B-intervention	0	11	Intrathecal
I-intervention	12	21	liposomal
I-intervention	22	32	cytarabine
I-intervention	33	37	plus
I-intervention	38	46	systemic
I-intervention	47	54	therapy
O	55	61	versus
B-control	62	70	systemic
I-control	71	83	chemotherapy
I-control	84	89	alone
O	90	93	for
O	94	99	newly
O	100	109	diagnosed
O	110	124	leptomeningeal
O	125	135	metastasis
O	136	140	from
O	141	147	breast
O	148	154	cancer
O	154	155	.

O	156	164	DEPOSEIN
O	165	166	(
O	166	177	NCT01645839
O	177	178	)
O	179	182	was
O	183	184	a
O	185	195	randomized
O	196	200	open
O	200	201	-
O	201	206	label
O	207	212	phase
O	213	216	III
O	217	222	study
O	223	225	to
O	226	233	explore
O	234	237	the
O	238	242	role
O	243	245	of
O	246	257	intrathecal
O	258	270	chemotherapy
O	271	273	in
O	274	282	patients
O	283	287	with
O	288	293	newly
O	294	303	diagnosed
O	304	318	leptomeningeal
O	319	329	metastasis
O	330	331	(
O	331	333	LM
O	333	334	)
O	334	335	,
O	336	337	a
O	338	344	common
O	345	358	manifestation
O	359	361	of
O	362	368	breast
O	369	375	cancer
O	375	376	.

B-eligibility	377	385	Patients
I-eligibility	386	390	with
I-eligibility	391	396	newly
I-eligibility	397	406	diagnosed
I-eligibility	407	409	LM
I-eligibility	410	417	defined
I-eligibility	418	420	by
I-eligibility	421	426	tumor
I-eligibility	427	432	cells
I-eligibility	433	435	in
I-eligibility	436	439	the
I-eligibility	440	453	cerebrospinal
I-eligibility	454	459	fluid
I-eligibility	460	462	or
I-eligibility	463	474	combination
I-eligibility	475	477	of
I-eligibility	478	486	clinical
I-eligibility	487	490	and
I-eligibility	491	503	neuroimaging
I-eligibility	504	509	signs
I-eligibility	510	512	of
I-eligibility	513	515	LM
O	516	520	were
O	521	531	randomized
O	532	534	to
O	535	542	receive
O	543	551	systemic
O	552	559	therapy
O	560	565	alone
O	566	567	(
O	567	574	control
O	575	580	group
O	580	581	)
O	582	584	or
O	585	593	systemic
O	594	601	therapy
O	602	606	plus
O	607	618	intrathecal
O	619	628	liposomal
O	629	639	cytarabine
O	640	641	(
O	641	653	experimental
O	654	659	group
O	659	660	)
O	660	661	.

B-outcome-Measure	662	673	Progression
I-outcome-Measure	673	674	-
I-outcome-Measure	674	678	free
I-outcome-Measure	679	687	survival
I-outcome-Measure	688	695	related
I-outcome-Measure	696	698	to
I-outcome-Measure	699	701	LM
I-outcome-Measure	702	703	(
I-outcome-Measure	703	705	LM
I-outcome-Measure	705	706	-
I-outcome-Measure	706	709	PFS
I-outcome-Measure	709	710	)
O	711	714	was
O	715	718	the
O	719	726	primary
O	727	735	endpoint
O	735	736	.

B-control-participants	737	743	Thirty
I-control-participants	743	744	-
I-control-participants	744	749	seven
O	750	753	and
B-intervention-participants	754	756	36
O	757	765	patients
O	766	770	were
O	771	779	assigned
O	780	782	to
O	783	786	the
O	787	794	control
O	795	798	and
O	799	802	the
O	803	815	experimental
O	816	822	groups
O	822	823	.

O	824	830	Median
O	831	837	number
O	838	840	of
O	841	850	liposomal
O	851	861	cytarabine
O	862	872	injections
O	873	875	in
O	876	879	the
O	880	892	experimental
O	893	898	group
O	899	902	was
O	903	904	5
O	905	906	(
O	906	911	range
O	912	913	1
O	913	914	-
O	914	916	20
O	916	917	)
O	917	918	.

B-outcome	919	924	Focal
I-outcome	925	937	radiotherapy
O	938	941	was
O	942	951	performed
O	952	954	in
B-cv-bin-abs	955	956	6
O	957	958	(
B-cv-bin-percent	958	960	16
I-cv-bin-percent	960	961	%
O	961	962	)
O	963	966	and
B-iv-bin-abs	967	968	3
O	969	970	(
B-iv-bin-percent	970	971	8
I-iv-bin-percent	971	972	%
O	972	973	)
O	974	982	patients
O	983	985	in
O	986	989	the
O	990	997	control
O	998	1001	and
O	1002	1014	experimental
O	1015	1021	groups
O	1021	1022	.

O	1023	1025	In
O	1026	1029	the
O	1030	1036	intent
O	1036	1037	-
O	1037	1039	to
O	1039	1040	-
O	1040	1045	treat
O	1046	1056	population
O	1056	1057	,
B-outcome	1058	1064	median
I-outcome	1065	1067	LM
I-outcome	1067	1068	-
I-outcome	1068	1071	PFS
O	1072	1075	was
B-cv-cont-median	1076	1077	2
I-cv-cont-median	1077	1078	.
I-cv-cont-median	1078	1079	2
I-cv-cont-median	1080	1086	months
O	1087	1088	(
O	1088	1090	95
O	1090	1091	%
O	1092	1094	CI
O	1094	1095	:
O	1096	1097	1
O	1097	1098	.
O	1098	1099	3
O	1099	1100	-
O	1100	1101	3
O	1101	1102	.
O	1102	1103	1
O	1103	1104	)
O	1105	1107	in
O	1108	1111	the
O	1112	1119	control
O	1120	1126	versus
B-iv-cont-median	1127	1128	3
I-iv-cont-median	1128	1129	.
I-iv-cont-median	1129	1130	8
I-iv-cont-median	1131	1137	months
O	1138	1139	(
O	1139	1141	95
O	1141	1142	%
O	1143	1145	CI
O	1145	1146	:
O	1147	1148	2
O	1148	1149	.
O	1149	1150	3
O	1150	1151	-
O	1151	1152	6
O	1152	1153	.
O	1153	1154	8
O	1154	1155	)
O	1156	1158	in
O	1159	1162	the
O	1163	1175	experimental
O	1176	1181	group
O	1182	1183	(
O	1183	1189	hazard
O	1190	1195	ratio
O	1196	1197	0
O	1197	1198	.
O	1198	1200	61
O	1200	1201	,
O	1202	1204	95
O	1204	1205	%
O	1206	1208	CI
O	1208	1209	:
O	1210	1211	0
O	1211	1212	.
O	1212	1214	38
O	1214	1215	-
O	1215	1216	0
O	1216	1217	.
O	1217	1219	98
O	1219	1220	)
O	1221	1222	(
O	1222	1223	P
O	1224	1225	=
O	1226	1227	0
O	1227	1228	.
O	1228	1230	04
O	1230	1231	)
O	1231	1232	.

O	1233	1240	Seventy
O	1240	1241	-
O	1241	1244	one
O	1245	1253	patients
O	1254	1258	have
B-outcome	1259	1263	died
O	1263	1264	.

B-outcome	1265	1271	Median
I-outcome	1272	1279	overall
I-outcome	1280	1288	survival
O	1289	1292	was
B-cv-cont-median	1293	1294	4
I-cv-cont-median	1294	1295	.
I-cv-cont-median	1295	1296	0
I-cv-cont-median	1297	1303	months
O	1304	1305	(
O	1305	1307	95
O	1307	1308	%
O	1309	1311	CI
O	1311	1312	:
O	1313	1314	2
O	1314	1315	.
O	1315	1316	2
O	1316	1317	-
O	1317	1318	6
O	1318	1319	.
O	1319	1320	3
O	1320	1321	)
O	1322	1324	in
O	1325	1328	the
O	1329	1336	control
O	1337	1343	versus
B-iv-cont-median	1344	1345	7
I-iv-cont-median	1345	1346	.
I-iv-cont-median	1346	1347	3
I-iv-cont-median	1348	1354	months
O	1355	1356	(
O	1356	1358	95
O	1358	1359	%
O	1360	1362	CI
O	1362	1363	:
O	1364	1365	3
O	1365	1366	.
O	1366	1367	9
O	1367	1368	-
O	1368	1369	9
O	1369	1370	.
O	1370	1371	6
O	1371	1372	)
O	1373	1375	in
O	1376	1379	the
O	1380	1392	experimental
O	1393	1398	group
O	1399	1400	(
O	1400	1406	hazard
O	1407	1412	ratio
O	1413	1414	0
O	1414	1415	.
O	1415	1417	85
O	1417	1418	,
O	1419	1421	95
O	1421	1422	%
O	1423	1425	CI
O	1425	1426	:
O	1427	1428	0
O	1428	1429	.
O	1429	1431	53
O	1431	1432	-
O	1432	1433	1
O	1433	1434	.
O	1434	1436	36
O	1436	1437	)
O	1438	1439	(
O	1439	1440	P
O	1441	1442	=
O	1443	1444	0
O	1444	1445	.
O	1445	1447	51
O	1447	1448	)
O	1448	1449	.

B-outcome	1450	1457	Serious
I-outcome	1458	1465	adverse
I-outcome	1466	1472	events
O	1473	1477	were
O	1478	1486	reported
O	1487	1489	in
B-cv-bin-abs	1490	1492	22
O	1493	1496	and
B-iv-bin-abs	1497	1499	30
O	1500	1508	patients
O	1508	1509	,
O	1510	1522	respectively
O	1522	1523	.

B-outcome	1524	1531	Quality
I-outcome	1532	1534	of
I-outcome	1535	1539	life
O	1540	1545	until
O	1546	1557	progression
O	1558	1561	did
O	1562	1565	not
O	1566	1572	differ
O	1573	1580	between
O	1581	1587	groups
O	1587	1588	.

O	1589	1592	The
O	1593	1601	addition
O	1602	1604	of
O	1605	1616	intrathecal
O	1617	1626	liposomal
O	1627	1637	cytarabine
O	1638	1640	to
O	1641	1649	systemic
O	1650	1659	treatment
O	1660	1668	improves
O	1669	1671	LM
O	1671	1672	-
O	1672	1679	related
O	1680	1683	PFS
O	1683	1684	.

O	1685	1697	Confirmatory
O	1698	1704	trials
O	1705	1709	with
O	1710	1719	optimized
O	1720	1727	patient
O	1728	1737	selection
O	1738	1746	criteria
O	1747	1750	and
O	1751	1755	more
O	1756	1762	active
O	1763	1768	drugs
O	1769	1772	may
O	1773	1775	be
O	1776	1784	required
O	1785	1787	to
O	1788	1799	demonstrate
O	1800	1801	a
O	1802	1810	survival
O	1811	1818	benefit
O	1819	1823	from
O	1824	1835	intrathecal
O	1836	1851	pharmacotherapy
O	1851	1852	.
